Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data
Allergy2017Vol. 73(3), pp. 576–584
Citations Over TimeTop 10% of 2017 papers
Petra Staubach, Martin Metz, Nadine Chapman‐Rothe, Christian Sieder, Matthias Bräutigam, Marcus Maurer, Karsten Weller
Abstract
Our findings support omalizumab treatment in patients with severe H1-antihistamine-refractory CSU with angioedema.
Related Papers
- → Effect of omalizumab on angioedema in H 1 ‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ ACT , a randomized controlled trial(2016)128 cited
- → The Potential Role of Omalizumab in the Treatment of Chronic Urticaria(2014)3 cited
- → Efficacy of Omalizumab for the Treatment of Allergic Urticaria and Angioedema(2007)2 cited
- → Effects of omalizumab on chronic urticaria not responding to recommended therapy(2012)
- → Private Practice Experience with Omalizumab for Chronic Urticaria(2020)